Eli Lilly and Co

Takeda receives approval from the Japanese Ministry of Health, Labour and Welfare for FRUZAQLA® (fruquintinib) for previously treated metastatic colorectal cancer, based on results from the global Phase III FRESCO-2 trial. FRUZAQLA® is the first novel targeted therapy approved in Japan for metastatic CRC in over a decade.

New entrants challenge Novo Nordisk and Eli Lilly in the $200 billion GLP-1 market, with 68% of sales from weight loss by 2031. Novo and Lilly expected to retain 70% of the market but are viewed as overvalued. Next-gen obesity drugs from Roche, Amgen, Pfizer, AstraZeneca, Boehringer, and others will disrupt the market, pressuring pricing. Novo and Lilly's next-gen pipelines also advancing. Public and private firms accelerating obesity drug development through acquisitions and innovative startups.

Teva Pharmaceuticals' Phase III SOLARIS trial and Phase I study of extended-release subcutaneous olanzapine, TEV-‘749, showed no cases of post-injection delirium/sedation syndrome (PDSS), a condition previously linked to olanzapine use. The SOLARIS study met its primary endpoint by improving schizophrenia symptoms, and the safety data was presented at the ECNP Congress in Milan.

Senator Bernie Sanders will lead a Senate HELP Committee hearing on Ozempic and Wegovy prices, focusing on price controls despite R&D costs and potential harm to medical innovation. The hearing aims to address the high cost of these diabetes medicines, but critics argue it overlooks the significant R&D investments required and the broader implications for future drug development.

Dr. Janese Laster discusses weight loss drugs, including Ozempic and Wegovy, their mechanisms, costs, insurance coverage, and the importance of lifestyle changes. She explains the differences between oral and injectable medications, their side effects, and the need for physician oversight. Cost varies, with injectables like Wegovy being more expensive, often around $1,500 to $2,000 a month without insurance. Lifestyle changes are crucial for sustained weight loss.

FDA approved Eli Lilly's EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for treating moderate-to-severe atopic dermatitis in adults and children 12+ years old who weigh at least 88 pounds and whose condition is not well controlled with topical prescription therapies. Results from studies ADvocate 1, 2, and ADhere showed 38% of treated patients achieved clear or almost-clear skin at 16 weeks, compared to 12% with placebo. EBGLYSS also provided itch relief, with 43% experiencing relief at 16 weeks, compared to 12% on placebo. The treatment was also approved in Europe and Japan, with additional market approvals expected.

Prime Minister Narendra Modi held a roundtable with tech CEOs in New York to boost India-US cooperation in AI, Quantum Computing, Biotechnology, Life Sciences, IT, and Semiconductors. Modi emphasized India's potential as a global tech hub, inviting companies to co-develop, co-design, and co-produce in India. CEOs expressed interest in expanding investments and collaborations, highlighting India's innovation-friendly policies and rapid digital expansion.

FDA approves Eli Lilly's EBGLYSS, a new drug targeting IL-13 cytokine to treat moderate-to-severe atopic dermatitis in adults and children 12+ years. Clinical trials showed 38% of participants had clear or nearly clear skin at 16 weeks, with 77% maintaining results at 1 year. Common side effects include eye inflammation and injection site reactions.

Healthcare marketing faces challenges like insurance denials and FDA regulations, requiring effective communication strategies. Marketers must bridge gaps between innovation and patient access, ensuring compliance while advocating for better healthcare access. Success stories like Eli Lilly's Mounjaro and Emgality highlight the complexities of off-label use and insurance coverage, emphasizing the need for patient-focused campaigns.

Prime Minister Modi interacted with tech CEOs in New York, focusing on AI, Quantum, Biotechnology, Computing, and Semiconductors. He emphasized India's commitment to becoming a global tech hub and protecting intellectual property, encouraging collaboration and innovation.